Company intelligence / Profile preview

LunGuard

Tel Aviv, Israelfinder.startupnationcentral.org ↗

Ownership: Private
Employees: ~3
Development stage: Other

Overview

LunGuard has developed a unique, patent-protected reflux prevention system for nasogastric tube-fed patients. The device has been successfully tested in both pre-clinical and clinical studies, demonstrating safety and effectiveness at reducing pulmonary aspirations and associated infections like VAP. The company projects significant sales following regulatory approval in the EU and US markets.

Therapeutic areas: GastroenterologyInfectious Diseases
Modalities: Device
Industry: Therapeutic Medical Devices

Beyond the preview

Go deeper on LunGuard.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LunGuard.

Explore the full profile